ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1938

The Pre-pregnancy Rheumatoid Arthritis Gene Expression Signature Correlates with Improvement or Worsening of Disease Activity During Pregnancy: A Pilot Study

Amogh Pathi 1, Mette Smed 2, Lior Pachter 3, Elizabeth Purdom 4, Matthew Wright 5, Nicholas Jewell 4, J. Lee Nelson 6, Jørn Olsen 7, Merete Lund Hetland 8, Vibeke Zoffmann 9 and Damini Jawaheer10, 1UCSF Benioff Children's Hospital Oakland, Oakland, 2Juliane Marie Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 3Caltech, Pasadena, 4University of California Berkeley, Berkeley, 5UCSF Benioff Children's Hopsital Oakland, Oakland, 6Fred Hutchinson Cancer Research Center, Seattle, 7Aarhus University Hospital, Aarhus, Denmark, 8DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 9Juliane Marie Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, 10UCSF Benioff Children's Hospital Oakland, Oakland, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Gene Expression and rna-seq, pregnancy, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Genetics, Genomics & Proteomics Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Pregnancy is known to induce a natural improvement of Rheumatoid Arthritis (RA) symptoms in 50-75% of patients as gestation progresses. However, the underlying mechanisms are not well understood and no biomarkers have been identified that predict whether a woman will improve or worsen during pregnancy. In this study, we aimed to identify RA-associated pre-pregnancy gene expression signatures to determine if they correlated with the subsequent improvement or worsening of RA during pregnancy.

Methods: Women with RA (n=11) and healthy women (n=5) were enrolled in our pregnancy cohort and followed prospectively. The women with RA were examined before pregnancy (T0) and at the third trimester (T3). Disease activity was assessed using Clinical Disease Activity Index (CDAI) scores. Blood was drawn from all women (RA and healthy) at both time-points. Total RNA was isolated and used to prepare cDNA libraries which were sequenced at an average depth of 60 million reads. The raw RNA sequencing (RNA-seq) data were pseudo-aligned to the reference Human transcriptome and quantified using kallisto. Genes differentially expressed between groups were identified with edgeR using a fold-change cutoff of 2 and significance threshold q< 0.05 (FDR corrected). Functional enrichment analysis was performed using Cytoscape.

Results: Of the 11 women with RA, 8 improved (RAimproved group) by T3 while 3 worsened (RAworsened group). At the T0 baseline, however, the mean disease activity scores were similar in both groups of women (RAimproved: 3.2±0.7; RAworsened: 3.5±1.4, p=0.7). When gene expression profiles of each RA subset was compared to the healthy women at T0, 94 genes were differentially expressed (q< 0.05; FC≥2) between the RAimproved and healthy women. These included CAMP, LGALS2, MAOA, S100A8, S100A9, S100A12 and a set of type I interferon inducible genes, many of which overlapped with previously reported RA expression signatures. A large proportion of the 94 differentially expressed genes clustered within 2 functional networks, one containing the over-expressed genes and the other containing the under-expressed genes. However, when the RAworsened women were compared to the healthy women at T0, a largely different RA-associated expression signature was identified. Of 83 genes that were differentially expressed, only 13 overlapped with those differentially expressed between RAimproved and healthy women at T0. The majority of the 83 genes did not appear to be enriched in any relevant biological pathways.

Conclusion: In our pilot dataset, the RA-associated gene expression signatures identified before pregnancy correlated with, and were thus predictive of, subsequent improvement or worsening during pregnancy, even though mean disease activity scores at the pre-pregnancy baseline were similar between the two RA subsets. These different expression signatures suggest that there may be inherent genomic differences between women with RA that dictate how pregnancy can alter disease activity.


Disclosure: A. Pathi, None; M. Smed, None; L. Pachter, None; E. Purdom, None; M. Wright, None; N. Jewell, None; J. Nelson, None; J. Olsen, None; M. Lund Hetland, Abbvie, 2, AbbVie, 2, Biogen, 2, BMS, 2, CellTrion, 2, 9, MSD, 2, Novartis, 2, Orion, 2, Pfizer, 2, Samsung, 2, UCB, 2; V. Zoffmann, None; D. Jawaheer, None.

To cite this abstract in AMA style:

Pathi A, Smed M, Pachter L, Purdom E, Wright M, Jewell N, Nelson J, Olsen J, Lund Hetland M, Zoffmann V, Jawaheer D. The Pre-pregnancy Rheumatoid Arthritis Gene Expression Signature Correlates with Improvement or Worsening of Disease Activity During Pregnancy: A Pilot Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-pre-pregnancy-rheumatoid-arthritis-gene-expression-signature-correlates-with-improvement-or-worsening-of-disease-activity-during-pregnancy-a-pilot-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-pre-pregnancy-rheumatoid-arthritis-gene-expression-signature-correlates-with-improvement-or-worsening-of-disease-activity-during-pregnancy-a-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology